Best Canadian Healthcare ETFs 2026: XHC vs ZUH vs HHL vs LIFE Compared
Canada's own healthcare sector is a rounding error on the TSX. The four ETFs that actually give Canadian investors real healthcare exposure are all Canadian-listed wrappers for US and global holdings. Here is how XHC, ZUH, HHL and LIFE differ on fees, yield, currency hedging and which account each one belongs in.
Why there is no pure-Canadian healthcare ETF
Health care sits at roughly 0.3 to 0.5 percent of the S&P/TSX Composite in 2026 - a fraction of the US S&P 500's 11 to 13 percent weight. The names that count as Canadian healthcare (Tilray, Bausch Health, a couple of specialty insurers and clinic operators) are too few and too concentrated to build a diversified index around. So every Canadian-listed healthcare ETF is really a Canadian wrapper for US or global holdings, sometimes CAD-hedged, sometimes not. This matters for currency risk, for withholding tax and for what happens when the US biotech cycle turns.
XHC: iShares Global Healthcare Index ETF (CAD-Hedged)
XHC tracks the MSCI World Health Care Index and hedges its non-CAD currency exposure back to Canadian dollars. It holds roughly 120 large- and mid-cap global healthcare names - the top ten typically includes Eli Lilly, Novo Nordisk, UnitedHealth, Johnson & Johnson, Roche, AbbVie, Merck, Pfizer, AstraZeneca and Thermo Fisher. The management fee is 0.61 percent (~0.66 percent MER after taxes), making it the second-cheapest option on this list. Because it is CAD-hedged, XHC removes the FX return that comes with holding US assets in a rising USD - useful when the loonie is strong, painful when it is weak. Distributions are quarterly and modest (around 1.2 to 1.5 percent yield).
ZUH: BMO Equal Weight US Health Care Hedged to CAD
ZUH holds about 60 US large-cap health care names in equal weight, rebalanced periodically so no single stock dominates the fund. MER is roughly 0.39 percent - the cheapest healthcare ETF listed in Canada. The equal-weight construction gives you meaningful exposure to the medical-device middle tier (Baxter, Zimmer Biomet, Waters, Hologic) that a cap-weighted fund like XHC would drown out under the pharma mega-caps. ZUH is US-only and CAD-hedged, so it strips out both international diversification and FX movement. Yield sits around 0.8 to 1.1 percent, distributed quarterly.
HHL: Harvest Healthcare Leaders Income ETF
HHL holds an equally weighted portfolio of 20 large-cap global healthcare stocks and writes covered calls on up to 33 percent of the portfolio to generate monthly income. That covered-call sleeve lets HHL distribute roughly 8 percent per year in monthly cash flow - most of which is treated as return of capital for tax purposes. The trade-off is a 1.20 percent MER (roughly triple XHC) and capped upside during strong single-stock rallies. HHL is currency-unhedged, so a rising USD boosts returns and a falling USD drags them.
LIFE: Evolve Global Healthcare Enhanced Yield ETF
LIFE is Evolve's answer to HHL - a covered-call healthcare fund with a very similar mandate. It holds about 20 large-cap global names, writes calls on around 33 percent of the portfolio, distributes monthly, and charges roughly 1.16 percent MER. LIFE tends to run slightly higher yield than HHL because its call-writing model is more aggressive, but that also means marginally more capped upside. Currency exposure is unhedged. In practice, if you are choosing between HHL and LIFE, look at the actual trailing 12-month total return net of fees - the two products track each other so closely that portfolio construction is the tiebreaker, not the marketing.
Side-by-side: fees, yield, holdings and hedging
| Metric | XHC | ZUH | HHL | LIFE |
|---|---|---|---|---|
| Issuer | iShares (BlackRock) | BMO | Harvest | Evolve |
| MER (2026) | ~0.66% | ~0.39% | ~1.20% | ~1.16% |
| Holdings | ~120 global | ~60 US | ~20 global | ~20 global |
| Weighting | Cap-weighted | Equal weight | Equal weight | Equal weight |
| Geographic split | ~65% US / ~35% intl | 100% US | ~80% US / ~20% intl | ~80% US / ~20% intl |
| Currency hedging | CAD-hedged | CAD-hedged | Unhedged | Unhedged |
| Distribution | Quarterly | Quarterly | Monthly | Monthly |
| Approx. yield | 1.2-1.5% | 0.8-1.1% | ~8.0% | ~8.2% |
| Covered calls? | No | No | Yes (up to 33%) | Yes (up to 33%) |
Prioritize growth (XHC or ZUH) if...
- You are 10+ years from needing income and want maximum total return
- You already have a diversified income sleeve elsewhere (dividend ETFs, bonds)
- You want the lowest possible drag from fees over a 20-30 year hold
- You are inside a TFSA or unregistered account where covered-call ROC accounting adds complexity
Prioritize income (HHL or LIFE) if...
- You are drawing down and need monthly cash flow to smooth your withdrawal rate
- You value the covered-call floor during flat or sideways healthcare markets
- You are comfortable capping upside during single-stock breakouts
- You are willing to pay 1.20% MER to have the option-writing done for you
Tax placement: which account each ETF belongs in
Every Canadian-listed healthcare ETF on this list holds mostly US stocks, and US dividend withholding tax follows the underlying holdings, not the wrapper. XHC and ZUH lose the standard 15 percent US withholding at the fund level regardless of which Canadian account holds them - that drag is baked into net returns. HHL and LIFE distribute most of their yield as return of capital, which reduces your adjusted cost base rather than triggering current tax, but the underlying US dividends still get hit for 15 percent at source.
ORDER OF OPERATIONS FOR A HEALTHCARE SLEEVE
- Check your world-equity core (XEQT, VEQT, VGRO, XGRO) - it already gives you ~10-13% healthcare weight through mega-cap pharma and health insurers.
- Decide whether you want to overweight the sector at all. If yes, cap the sleeve at 5-8% of total equity so a bad biotech year does not wreck your plan.
- Pick your primary lens: growth (XHC or ZUH), income (HHL or LIFE), or a mix of both.
- For growth: use ZUH if you want the lowest fee and equal-weight US exposure; use XHC if you want global diversification (35% ex-US) and cap-weighted mega-caps.
- For income: check trailing 12-month total return (not just yield) for HHL vs LIFE and pick whichever your broker charges less to trade.
- Place US-heavy funds inside your RRSP first if you can, so any US-listed alternatives you add (VHT, XLV) get the withholding recovery.
What to actually pick in 2026
If you are building a low-cost, long-term growth allocation and want the smallest fee drag, ZUH is the winner - 0.39 percent MER, equal-weighted US exposure, and no covered-call complexity to reconcile at tax time. If you want global diversification with the ex-US pharma names (Novo Nordisk, Roche, AstraZeneca), pick XHC and accept the extra 25 basis points for the international sleeve and cap-weighted construction. If your primary need is monthly cash flow to fund retirement withdrawals or supplement a pension, HHL or LIFE is the answer - just make sure the 1.20 percent fee is buying you meaningful income, not just capped upside.
Frequently asked questions
Is there a pure-Canadian healthcare ETF?
No. Health care is only about 0.3 to 0.5 percent of the S&P/TSX Composite, dominated by a handful of names like Tilray Brands, Bausch Health and a couple of insurers. There is no viable Canada-only healthcare ETF because the sector is too small and too concentrated. Every product with "Canadian" in the marketing (XHC, ZUH, HHL, LIFE) is a Canadian-listed wrapper for global or US healthcare exposure.
What is the cheapest Canadian healthcare ETF?
ZUH from BMO at roughly 0.39 percent MER is the cheapest healthcare ETF listed in Canada for 2026. XHC from iShares comes next at 0.66 percent (0.61 percent management fee plus taxes). The Harvest and Evolve covered-call products (HHL, LIFE) sit at 1.16 to 1.20 percent, and that gap compounds into a real drag over 20 to 30 years.
Should I hold XHC in my TFSA or RRSP?
Either works but the math nudges you toward RRSP for US-listed holdings. XHC is CAD-hedged and Canadian-listed so it does not directly suffer the 15 percent US dividend withholding tax inside a TFSA. However, the underlying US positions inside the fund still lose 15 percent to withholding at the fund level regardless of your account. If you would rather hold a US-listed healthcare ETF directly (like VHT or XLV), the RRSP is the only Canadian account that recovers that 15 percent under the tax treaty.
Are covered-call healthcare ETFs like HHL worth the higher fee?
Only if you actually need the monthly income and can accept capped upside. HHL yields around 8 percent by writing calls on roughly 33 percent of its holdings, which caps upside during strong pharma rallies (like weight-loss drug moves in 2023 to 2025). Over a full cycle, plain-vanilla XHC or ZUH has historically delivered better total return. HHL only wins if you value predictable monthly distributions more than long-run compounding.
How much of my portfolio should be in healthcare?
A cap-weighted world equity ETF (like XEQT, VEQT or a US total-market ETF) already holds 10 to 13 percent healthcare through Eli Lilly, Novo Nordisk, UnitedHealth, Johnson & Johnson and dozens of others. A separate healthcare ETF is a sector tilt on top of that. Most investors who want an overweight cap the sleeve at 5 to 8 percent of total equity - enough to matter, not enough to blow up if biotech has a bad year.
What is the difference between XHC and ZUH exposure?
XHC tracks MSCI World Health Care and holds roughly 65 percent US plus 35 percent international (Novo Nordisk, Roche, AstraZeneca, Sanofi). ZUH is US-only, equal-weighted across about 60 large-cap US health care names, so no single company can dominate. XHC gives you global diversification and a lower total cost of ownership; ZUH gives you higher small and mid-cap tilt within US healthcare and avoids concentration in whichever mega-cap is having its moment.